Skip to content
Open access

The lymphocyte function of allogeneic peripheral blood stem cell grafts is associated with relapse and cytomegalovirus reactivation.

Aug 2026 · Transfusion · 0 citations · 34 references
Medicine

TL;DR

Measurement of the lymphocyte response upon mitogen stimulation of PBSC grafts might provide beneficial knowledge of graft-related factors that contribute to the incidence of complications after HSCT.

Abstract

Background

Allogeneic hematopoietic stem cell transplantation (HSCT) is a treatment primarily for hematological malignancies. Infections, relapse, and graft versus host disease (GvHD) are some of the most common adverse events following HSCT. We aimed to evaluate whether the lymphocyte function of the stem cell graft was associated with these events. STUDY

Design

AND

Methods

We included peripheral blood stem cell (PBSC) grafts from 53 donors to HSCT recipients. The grafts' lymphocyte function was assessed by in vitro blast formation, expression of activation markers, and cytokine production upon stimulation. The cellular composition of the grafts was determined with flow cytometry. Results were compared with the incidence of infections, GvHD, relapse, and survival in the HSCT recipients.

Results

We found an association between lower graft T cell response upon mitogen or superantigen stimulation and cytomegalovirus reactivation (p = .013 and p = .0028). Recipients of grafts with an above-median programmed death-1 (PD-1) expression on CD8+ T cell blasts had a higher incidence of relapse and lower overall survival (p = .02). Both findings remained significant in the multivariable analysis.

Discussion

Measurement of the lymphocyte response upon mitogen stimulation of PBSC grafts might provide beneficial knowledge of graft-related factors that contribute to the incidence of complications after HSCT.

Read PDF

Similar papers

Jul 2026

Development of a Protective Cellular Therapy to Prevent Graft Versus Host Disease Post Allogenic Hematopoietic Stem Cell Transplant 2331939

Results affirm PLZF overexpression as a viable, programmable approach for GVHD prophylaxis, poised for clinical advancement and hold promise for revolutionizing allo-HSCT by decoupling immune tolerance from antitumor immunity.

Jake Cox, Dhruti Patel, Steven Montecinos Montes et al. · 0 citations
Sep 2026

Impact of graft-versus-host disease on relapse and survival in adults with B-cell acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation plus post-transplant cyclophosphamide in resource-limited settings.

Allogeneic hematopoietic stem cell transplantation (HSCT) is an effective treatment for B-cell acute lymphoblastic leukemia (B-cell ALL). An important mechanism for the prevention of relapse is the graft-versus-leukemia (GVL) effect, potentially at the expense of the accompanying graft-versus-host disease (GVHD), which...

C. Gutiérrez-Aguirre, F. De la Garza-Salazar, J. Jaime-Pérez et al. · 0 citations
Open access Jul 2026

Immune reconstitution and viral reactivation after allogeneic hematopoietic stem cell transplantation in hematologic malignancies.

Intermediate immune-reconstitution landmarks showed distinct associations with surveillance-defined viral reactivation, particularly six-month B-cell proportion for CMV and CD8⁺ T-cell recovery in the context of chronic GVHD for EBV.

M. Qaiser, Hao Zhou, Guangyu Zhou et al. · 0 citations
Open access Jul 2026

Lymphoid Tissue-Activated Donor T cells (LADTs) for Improved Donor Lymphocyte Infusion (DLI) against Blood Cancers 2250463

The feasibility of LADT generation and the proof-of-concept of using LADTs for improved DLI are demonstrated and the cellular immunotherapy approach does not depend on cancer-specific biomarkers thus may be applied to a wide range of hematopoietic malignancies.

Yasemin Kuş, K. Christie, Shen-Yu Zhang et al. · 0 citations
Aug 2026

Immune cell subsets that predict cytomegalovirus reactivation magnitude after haematopoietic stem cell transplantation.

A 21-parameter spectral cytometry antibody panel is developed to characterise peripheral blood mononuclear cells from adult allogeneic HSCT-recipients at four timepoints over the course of HCMV reactivation, including before and at initial detection of HCMV DNAemia.

Danya Kaplan, E. Blyth, Selmir Avdic et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.